Mark W. Hahn, Chief Financial Officer at Verona Pharma plc (VRNA), sold 774,016 shares at $9.09 ($7.0M) on 2025-05-02, disclosed to the SEC on 2025-05-05.
Scheduled sale ($7.0M) by Chief Financial Officer under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $8.95 | 78,736 | $705K | 10.1% |
| 2 | $8.95 | 78,736 | $705K | 10.1% |
| 3 | $8.95 | 108,272 | $969K | 13.9% |
| 4 | $8.95 | 108,272 | $969K | 13.9% |
| 5 | $9.09 | 400,000 | $3.6M | 52.1% |
| Total | $9.02 avg | 774,016 |
| $7.0M |
| 100% |
| Filing → |
| VRNA | SELL | 2025-05-29 | $7.5M | — | Filing → |
| VRNA | SELL | 2025-05-01 | $1.6M | — | Filing → |
| VRNA | SELL | 2024-12-06 | $8.5M | — | Filing → |